Clinical Trial Update: A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota [Phase 2]

View source ↗

Summary

Phase 2 trial investigating differential effects of inhaled Symbicort and Advair on lung microbiota in COPD patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Advair (fluticasone propionate/salmeterol)
• Symbicort (budesonide/formoterol)

Snippet

Sponsor: University of British Columbia | Conditions: Chronic Obstructive Pulmonary Disease | Phase 2 | Status: UNKNOWN